You’d hope they’ve gotten some US based funds interested. The exposure they would offer might be worth the dilution. Plenty of capital raises (If done for growth/commercial progress rather than ‘working capital’) end up being net positive for market cap in the medium term. This won’t stay below $1 billion if it becomes an established FDA approved therapy, just on potential alone.
Ann: Trading Halt, page-19
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.005(0.46%) |
Mkt cap ! $332.7M | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.12 | $1.03 | $155.3K | 147.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 6875 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| EBR (ASX) Chart |